Insulet Corporation (PODD)
NASDAQ: PODD · Real-Time Price · USD
143.34
-3.10 (-2.12%)
At close: Aug 14, 2026, 4:00 PM EDT
142.50
-0.84 (-0.59%)
Pre-market: Aug 17, 2026, 7:50 AM EDT
Insulet Revenue
Insulet had revenue of $801.70M in the quarter ending June 30, 2026, with 23.51% growth. This brings the company's revenue in the last twelve months to $3.05B, up 29.41% year-over-year. In the year 2025, Insulet had annual revenue of $2.71B with 30.73% growth.
Revenue (ttm)
$3.05B
Revenue Growth
+29.41%
P/S Ratio
3.26
Revenue / Employee
$565,444
Employees
5,400
Market Cap
9.94B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.71B | 636.50M | 30.73% |
| Dec 31, 2024 | 2.07B | 374.50M | 22.07% |
| Dec 31, 2023 | 1.70B | 391.80M | 30.02% |
| Dec 31, 2022 | 1.31B | 206.50M | 18.79% |
| Dec 31, 2021 | 1.10B | 194.40M | 21.49% |
| Dec 31, 2020 | 904.40M | 166.20M | 22.51% |
| Dec 31, 2019 | 738.20M | 174.40M | 30.93% |
| Dec 31, 2018 | 563.80M | 100.00M | 21.56% |
| Dec 31, 2017 | 463.80M | 96.81M | 26.38% |
| Dec 31, 2016 | 366.99M | 103.10M | 39.07% |
| Dec 31, 2015 | 263.89M | 32.57M | 14.08% |
| Dec 31, 2014 | 231.32M | -15.76M | -6.38% |
| Dec 31, 2013 | 247.08M | 35.72M | 16.90% |
| Dec 31, 2012 | 211.37M | 59.11M | 38.83% |
| Dec 31, 2011 | 152.26M | 55.29M | 57.02% |
| Dec 31, 2010 | 96.97M | 30.93M | 46.85% |
| Dec 31, 2009 | 66.03M | 29.97M | 83.12% |
| Dec 31, 2008 | 36.06M | 22.69M | 169.66% |
| Dec 31, 2007 | 13.37M | 9.71M | 265.06% |
| Dec 31, 2006 | 3.66M | 3.61M | 7,226.00% |
| Dec 31, 2005 | 50.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zimmer Biomet Holdings | 8.51B |
| Smith & Nephew | 6.30B |
| STERIS | 6.04B |
| Bruker | 3.50B |
| Globus Medical | 3.14B |
| Bio-Rad Laboratories | 2.59B |
| Bio-Rad Laboratories | 2.59B |
| Integer Holdings | 1.84B |
PODD News
- 21 hours ago - Insulet participates in a conference call with JPMorgan - TheFly
- 3 days ago - Contact Robbins LLP for Information About Leading the Lawsuit That Alleges Insulet Corporation Misled Investors Regarding the Safety and Reliability of its Insulin Delivery Products - GlobeNewsWire
- 4 days ago - Insulet Corporation Investors With Significant Losses Must Act By August 31, 2026 - GlobeNewsWire
- 5 days ago - SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 31, 2026 in Insulet Corporation Lawsuit - PODD - GlobeNewsWire
- 10 days ago - Insulet price target lowered to $175 from $248 at Baird - TheFly
- 10 days ago - Insulet price target lowered to $180 from $190 at Deutsche Bank - TheFly
- 10 days ago - Leerink downgrades Insulet to Market Perform, lowers target to $145 - TheFly
- 10 days ago - Insulet price target lowered to $144 from $294 at TD Cowen - TheFly